Vanda Pharmaceuticals Inc (VNDA)
5.58
+0.22
(+4.10%)
USD |
NASDAQ |
May 16, 16:00
5.585
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | |
| December 31, 2022 | 0.605M |
| September 30, 2022 | 0.004M |
| June 30, 2022 | 0.125M |
| March 31, 2022 | |
| December 31, 2021 | 1.041M |
| September 30, 2021 | 0.371M |
| June 30, 2021 | 0.289M |
| March 31, 2021 | 1.849M |
| December 31, 2020 | 1.432M |
| September 30, 2020 | 0.123M |
| June 30, 2020 | 3.60M |
| March 31, 2020 | 0.479M |
| December 31, 2019 | 2.116M |
| September 30, 2019 | 0.558M |
| June 30, 2019 | 3.411M |
| March 31, 2019 | 0.179M |
| December 31, 2018 | 0.792M |
| September 30, 2018 | 0.112M |
| June 30, 2018 | 2.488M |
| March 31, 2018 | 103.73M |
| December 31, 2017 | 0.081M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.768M |
| June 30, 2017 | 2.193M |
| March 31, 2017 | 2.209M |
| December 31, 2016 | 0.75M |
| September 30, 2016 | 5.962M |
| June 30, 2016 | 1.015M |
| March 31, 2016 | 0.024M |
| December 31, 2015 | -0.001M |
| September 30, 2015 | 3.579M |
| June 30, 2015 | 0.592M |
| March 31, 2015 | -0.079M |
| December 31, 2014 | 87.49M |
| September 30, 2014 | 0.198M |
| June 30, 2014 | 0.032M |
| March 31, 2014 | 2.011M |
| December 31, 2013 | 0.441M |
| September 30, 2013 | 48.82M |
| June 30, 2013 | 0.794M |
| March 31, 2013 | -0.193M |
| December 31, 2012 | 0.012M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.02M |
| September 30, 2011 | 0.005M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2023
3.60M
Maximum
Jun 2020
0.9414M
Average
0.479M
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| ADMA Biologics Inc | -1.447M |
| INVO Bioscience Inc | -0.1415M |
| Johnson & Johnson | 546.00M |
| Nektar Therapeutics | 42.00M |
| Invivyd Inc | 39.10M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 7.569M |
| Cash from Investing (Quarterly) | -18.22M |
| Free Cash Flow | -11.77M |
| Free Cash Flow Per Share (Quarterly) | 0.1309 |
| Free Cash Flow to Equity (Quarterly) | 7.562M |
| Free Cash Flow to Firm (Quarterly) | 7.562M |
| Free Cash Flow Yield | -3.66% |